Labiotech.eu

News and Trends 28 Jun 2015

Google and big names helped Oxford Sciences Innovation to raise €457M

Oxford Sciences Innovation has completed the second close of its fundraising, raising an additional €157.3M (£110M) and bringing the total amount raised to €457.6M (£320M). This second close included some well-known investors such as Google Ventures and Charles Dunstone. Being backed by one of the best-recognized institutions in the world has its advantages. Oxford University […]

June 28, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 25 Jun 2015

AstraZeneca’s senior managers are abandoning ship

In just a couple of weeks, AstraZeneca has seen two of its chiefs leave their position to run two smaller biotechs. James Ward-Lilley made his exist from Astra to become CEO of Vectura, just a few days after Briggs Morrison abruptly left to also become CEO of Syndax. The rich also cry, said the telenovela and […]

June 25, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 25 Jun 2015

BioNTech and Siemens to build a new Production plant for Personalized Cancer Vaccines

Personalized medicine is the next thing and immunotherapy expert BioNTech is determined to build its place in this competitive field. With this purpose in mind, the German biotech will partner with Siemens to build a new production plant for personalized cancer vaccines. Founded in 2008, the BioNTech Group has become one of the fastest-growing biotechnology […]

June 25, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 25 Jun 2015

Video: Discover How CAR-T Therapies are Working

It’s becoming a habit for us to talk about CAR-T therapies. It’s basically the next wave of treatments against cancer and already promises to be the future blockbusters and growth drivers of the whole Biotech industry. Cellectis, a leading company in this field, just published a cool video about CAR-Ts. Of course, they’re describing more specifically their own therapy, […]

June 25, 2015 - 1 minutemin - By Joachim Eeckhout

News and Trends 25 Jun 2015

A treatment for Spinal Muscular Atrophy received Orphan Drug designation

The European Medicines Agency has granted Orphan Drug designation to AveXis’ gene transfer candidate. The therapy is currently in clinical development in the United States for the treatment of type 1 Spinal Muscular Atrophy and already received Orphan Drug designation for this disease in the United States. Spinal Muscular Atrophy is an autosomal-recessive genetic disorder […]

June 25, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 24 Jun 2015

AYOXXA and Grünenthal collaborate on inflammation markers

AYOXXA Biosystems and Grünenthal have completed their first research collaboration to validate detection limits for a biomarker based on AYOXXA’s platform. The outcomes of this collaboration can be applied in several fields that include biological samples with very low initial volume, previously inaccessible by other immunoassays. The focus of the joint study consisted in analyzing […]

June 24, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 23 Jun 2015

DBV Technologies to cure Peanut allergy

DBV Technologies plans the initiation of its phase III clinical trial for Viaskin Peanut, after a satisfactory conclusion of the phase II. The drug candidate already achieved a positive opinion from the Paediatric Committee of the European Medicines Agency. Both FDA and EMA desire to move forward with the development of what may be the […]

June 23, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 23 Jun 2015

Chris Viehbacher to run Swiss billionaire’s investment fund

One of our favorite bio-celebrities is enlarging his CV with a new job position. The German-Canadian Chris Viehbacher will run the billionaire Gurnet Point Capital fund, owned by the Swiss magnate Ernesto Bertarelli. If Chris Viehbacher felt disappointed after being dumped from Sanofi, at least he didn’t lose his pharma thrill. Recently, however, the business […]

June 23, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 23 Jun 2015

Will Boehringer Ingelheim win the race for anticoagulants?

Boehringer Ingelheim has released the last figures of its idarucizumab Phase III. The breakthrough anti-anticoagulant is being studied as an antidote to Boehringer’s blockbuster Pradaxa. Pradaxa was the first widely approved drug in a new generation of direct oral anticoagulants, a blockbuster developed by Boehringer Ingelheim. However, there is no specific antidote available yet to […]

June 23, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 22 Jun 2015

Kamada and Baxter extend their collaboration in Lung Transplant

The Israeli biotech Kamada and Baxalta, Baxter’ subsidiary will jointly co-fund a trial test to find out whether Kamada’s candidate is capable of preventing lung transplant rejection. Kamada, a plasma-derived protein therapeutics company focused on orphan indications, will carry out a Phase I/II clinical trial of its candidate alpha-1 antirypsin (AAT). The protein was already approved for […]

June 22, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 22 Jun 2015

A Dutch entrepreneur curing his ALS disease became BIO’s Superhero

Each year, BIO Philadelphia awards the Everyday Superheroes of Biotech Industry. Here’s the story of Bernard Muller, co-founder of Treeway, a Dutch biotech company focused on the treatment of Amyotrophic lateral sclerosis (ALS). Bernard Muller is an extraordinary person, being himself a ALS patient and an entrepreneur who started his own Biotech company. Last week, we were talking […]

June 22, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 22 Jun 2015

Medigene plans to fund its T-cell program with €50 Millions

Munich-based Medigene is planning to raise cash through existing shareholders’ investments. The company targets up to €50M to propel its immune-oncology program with T-Cell Receptors and Dendritic Cells vaccines assets. Medigene plans a cash capital increase with subscription rights for existing shareholders by offering a new batch of shares. The company is going to present […]

June 22, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Google and big names helped Oxford Sciences Innovation to raise €457M

AstraZeneca’s senior managers are abandoning ship

BioNTech and Siemens to build a new Production plant for Personalized Cancer Vaccines

Video: Discover How CAR-T Therapies are Working

A treatment for Spinal Muscular Atrophy received Orphan Drug designation

AYOXXA and Grünenthal collaborate on inflammation markers

DBV Technologies to cure Peanut allergy

Chris Viehbacher to run Swiss billionaire’s investment fund

Will Boehringer Ingelheim win the race for anticoagulants?

Kamada and Baxter extend their collaboration in Lung Transplant

A Dutch entrepreneur curing his ALS disease became BIO’s Superhero

Medigene plans to fund its T-cell program with €50 Millions

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!